Nanofluidics

Fluid behavior and devices at the nanoscale

50 companies 13 countries
P

Porifera

Hayward, United States

Developer of forward osmosis membranes using carbon nanotube and graphene oxide

N

NanoMedical Systems

Austin, United States

Developer of nanochannel drug delivery implants for sustained therapeutic release

P

Precision NanoSystems

Vancouver, Canada

Provider of instruments for scalable nanoparticle manufacturing for gene therapies and mRNA vaccines

1

10x Genomics

Pleasanton, United States

10x Genomics, founded in 2012 in Pleasanton, California, has revolutionized biological research through innovative microfluidic and nanoscale technologies that enable unprecedented resolution in genomics analysis. The company went public on NASDAQ under ticker TXG, reflecting its status as a major player in the genomics technology sector with over 1,000 employees worldwide. 10x Genomics specializes in single-cell analysis and spatial biology, utilizing sophisticated nanofluidic systems that manipulate individual cells and molecules within nanoliter-scale droplets and nanofabricated chambers. The company's flagship Chromium platform employs microfluidic partitioning to isolate individual cells into nanoliter-sized gel beads in emulsion (GEMs), where each cell receives a unique molecular barcode. This nanotechnology-enabled approach allows researchers to analyze gene expression, immune repertoires, and epigenetic states at single-cell resolution, revealing cellular heterogeneity previously obscured in bulk tissue analysis. The Visium spatial genomics platform combines tissue imaging with transcriptomics, using nanoscale capture arrays to map gene expression while preserving spatial context within tissue sections. The newer Xenium in situ platform pushes resolution further, enabling subcellular visualization of hundreds of genes simultaneously through multiplexed in situ hybridization with nanoscale precision. These technologies rely on advanced nanofabrication techniques, precise microfluidic control, and molecular barcoding strategies that operate at nanometer scales. 10x Genomics products have become essential tools in cancer research, immunology, neuroscience, and developmental biology, enabling discoveries about cellular diversity, disease mechanisms, and therapeutic targets. The company's success demonstrates how nanotechnology enables transformative advances in life sciences, making previously impossible measurements routine. With continued innovation in nanofluidics, molecular barcoding, and imaging technologies, 10x Genomics continues to expand the frontiers of biological understanding at the single-cell and subcellular levels.

NASDAQ: TXG
N

Nanobix

Basel, Switzerland

Nanobix, founded in 2018 in Basel, Switzerland, is an innovative biotechnology company developing next-generation nanopore-based biosensors for rapid point-of-care diagnostics. Based in Basel, a global hub for pharmaceutical and biotechnology innovation, Nanobix leverages cutting-edge nanotechnology to create diagnostic devices that can detect disease biomarkers quickly and accurately outside traditional laboratory settings. The company's nanopore biosensor platform utilizes nanoscale pores—typically 1-10 nanometers in diameter—embedded in thin membranes as highly sensitive molecular detectors. When target molecules pass through or interact with these nanopores under an applied electrical field, they produce characteristic changes in ionic current that serve as molecular fingerprints for identification and quantification. This single-molecule detection approach offers exceptional sensitivity and specificity, enabling detection of biomarkers at clinically relevant concentrations from small sample volumes. Nanobix's technology addresses critical needs in point-of-care diagnostics, where rapid results can significantly impact patient management and treatment decisions. The nanopore platform is particularly well-suited for detecting nucleic acids, proteins, and other biomolecules associated with infectious diseases, cancer, and cardiovascular conditions. Unlike conventional diagnostic methods requiring extensive sample preparation and laboratory infrastructure, nanopore sensors can potentially deliver results in minutes from raw or minimally processed samples. The company has secured over $5 million in funding to advance its platform through development and validation stages. Switzerland's strong scientific ecosystem, with world-class universities and research institutions, provides Nanobix with access to expertise in nanofabrication, biosensor development, and clinical diagnostics. The company's work represents an important advancement in translating nanopore technology, originally developed for DNA sequencing, into broader diagnostic applications. As healthcare systems increasingly emphasize decentralized testing and rapid diagnosis, Nanobix's nanopore biosensors could play a significant role in bringing laboratory-quality diagnostics to point-of-care settings worldwide.

O

Oxford Nanopore Technologies

Oxford, United Kingdom

Pioneer in nanopore DNA/RNA sequencing technology enabling real-time, long-read sequencing

LSE: ONT
P

Pacific Biosciences

Menlo Park, United States

Developer of single molecule real-time (SMRT) DNA sequencing technology

NASDAQ: PACB
I

Illumina

San Diego, United States

Global leader in DNA sequencing using nanoscale flow cell technology

NASDAQ: ILMN
B

Boston Micro Fabrication

Maynard, United States

Developer of micro-precision 3D printing systems

S

Silex Microsystems

Jarfalla, Sweden

Pure-play MEMS foundry for advanced microsystems

N

Nabsys

Providence, United States

Developer of electronic genome mapping using nanochannels

N

Nutcracker Therapeutics

Emeryville, United States

Automated mRNA manufacturing with microfluidic systems

N

NanoEnTek

Seoul, South Korea

Lab-on-a-chip and cell analysis systems

C

CNRS LAAS

Toulouse, France

French national MEMS and nano research center

research
S

Standard BioTools

South San Francisco, United States

Microfluidics and mass cytometry for life science research

NASDAQ: LAB public
N

Nuclera

Cambridge, United Kingdom

Desktop protein synthesis and bioprinting technology

S

Sphere Fluidics

Cambridge, United Kingdom

Picodroplet microfluidics for single-cell analysis and antibody discovery

D

Dolomite Microfluidics

Royston, United Kingdom

Microfluidic systems for droplet generation and particle synthesis

F

Fluigent

Paris, France

Pressure-based microfluidic flow control systems for research

M

Micronit

Enschede, Netherlands

Glass and silicon microfluidic chips manufacturing for life sciences

C

Cepheid

Sunnyvale, United States

Molecular diagnostics with microfluidic cartridges and nanoscale detection

M

Merck Millipore

Darmstadt, Germany

Lab filtration and bioprocessing with nanopore membrane technology

XETRA: MRK public
N

NanoEnTek

Seoul, South Korea

Microfluidics and nano-scale diagnostic devices for life sciences

N

NanoCellect Biomedical

San Diego, United States

Microfluidic cell sorting for single-cell applications

D

Dolomite Microfluidics

Royston, United Kingdom

Microfluidic systems for droplet generation and particle synthesis

R

RainDance Technologies (Bio-Rad)

Billerica, United States

Droplet digital PCR technology, acquired by Bio-Rad

M

MEMSCAP

Grenoble, France

Custom MEMS solutions and foundry services

Euronext: MEMS public
M

MEMSPRO (CSEM)

Neuchâtel, Switzerland

MEMS R&D and technology transfer center

research
A

Aspect Biosystems

Vancouver, Canada

Microfluidic bioprinting for tissue therapeutics and drug delivery applications

I

Iron Ox

Gilroy, United States

Fully autonomous robot farms growing produce using AI and robotics

K

Koniku

San Jose, United States

Wetware company merging synthetic biology with silicon for neuromorphic computing

S

Starfish Space

Kent, United States

Spacecraft servicing company developing autonomous docking technology

P

Phase Four

Hawthorne, United States

Plasma propulsion company for small satellites

B

Berkeley Lights

Emeryville, United States

Digital cell biology company using optoelectronic positioning for single cell manipulation

I

Insulet Corporation

Acton, United States

Medical device company developing tubeless insulin pump technology

NASDAQ: PODD public
C

CareDx

Brisbane, United States

Precision medicine company focused on transplant diagnostics

NASDAQ: CDNA public
S

Skillz

San Francisco, United States

Mobile esports platform for competitive gaming tournaments

NYSE: SKLZ public
B

Buffalo Automation

Buffalo, United States

AI-powered autonomous marine vessels

P

PortXchange

Rotterdam, Netherlands

Port call optimization and collaboration

M

Meituan

Beijing, China

Food delivery and local services

HKG: 3690 public
G

Grab

Singapore, Singapore

Grab is Southeast Asia's leading superapp platform offering ride-hailing, food delivery, digital payments, and financial services across eight countries including Singapore, Indonesia, Malaysia, Thailand, Vietnam, Philippines, Myanmar, and Cambodia. Founded in 2012 in Singapore (originally as MyTeksi in Malaysia) and publicly traded on NASDAQ under ticker GRAB, the company employs over 10,000 people and serves millions of users daily. Grab's ride-hailing service dominates most Southeast Asian markets, offering motorcycles, cars, and taxi services tailored to local preferences and infrastructure. GrabFood has become the region's largest food delivery platform, partnering with hundreds of thousands of restaurants and merchants. GrabMart provides on-demand delivery of groceries and essentials from supermarkets, convenience stores, and specialty retailers. GrabExpress offers same-day parcel delivery for businesses and consumers. GrabPay, the company's digital wallet, enables cashless payments across Grab services and at millions of merchant locations, becoming a significant player in Southeast Asia's digital payments ecosystem. GrabFinancial extends into lending, insurance, and investment products designed for the region's largely underbanked population. The platform's success stems from deep localization, understanding diverse market needs from motorcycle taxis in dense cities to car services in suburban areas. Grab's driver and merchant partners number in the millions, providing critical earning opportunities across the region. The superapp strategy creates network effects where users access multiple services through one platform, increasing engagement and lifetime value. With Southeast Asia's young, mobile-first population and rapidly growing middle class, Grab is positioned as essential digital infrastructure for the region's economic development and digital transformation.

NASDAQ: GRAB public
S

Swiftly

San Francisco, United States

Transit data platform

M

Moovit

Ness Ziona, Israel

Mobility as a Service platform

N

Nanion Technologies

Munich, Germany

Automated patch clamp and ion channel research

M

Micralyne

Edmonton, Canada

MEMS and microfluidics foundry services

E

Elveflow

Paris, France

Microfluidic instruments for nanoparticle synthesis

T

TeraPore Technologies

South San Francisco, United States

Block copolymer-based nanofiltration membranes

E

Envue Technologies

Stockholm, Sweden

Nanofluidic scattering microscopy for protein and biomolecule characterization

N

Nexalus

Dublin, Ireland

Impinging liquid jet CPU cooling technology

C

Coolit Systems

Calgary, Canada

Direct liquid cooling solutions for data centers